India's Glenmark Pharma announces discovery of new monoclonal antibody
MUMBAI Feb 4 (Reuters) - Indian drugmaker Glenmark Pharmaceuticals said on Monday it has discovered a new molecule that can be used to treat diseases such as rheumatoid arthritis and inflammatory bowel disease.
The new molecule, named GBR 830, is an anti-OX40 monoclonal antibody, Glenmark said in a statement, adding that OX40 is responsible for some autoimmune diseases.
The company said it has initiated studies for an investigational new drug (IND) application to be filed with the U.S. Food and Drug Administration. (Reporting by Kaustubh Kulkarni in Mumbai; Editing by Jijo Jacob)
- Ukraine says Russian tanks flatten town; EU to threaten more sanctions |
- F-16s dispatched for unresponsive pilot of small plane near D.C.
- EU wields Russia sanctions threat but timing vague |
- Polish president warns Germany of Putin's 'empire' ambitions
- Trapped peacekeepers at Golan Heights moved to secure area: Philippine military chief